COMPANY PROFILE · /insilico-medicine
I
Insilico Medicine
Clinical-stage biotech using generative AI for end-to-end drug discovery. Proprietary Pharma.AI platform integrates LLMs, multimodal foundation model (Nach01), and Dora research assistant. First fully AI-discovered molecule in Phase 2 trials.
Fresh · 9d ago
Latest valuation
—
Annual Recurring Revenue
—
Headcount
180+
Funding total
$500M+
OVERVIEW
Raised $110M Series E in March 2025 (led by Value Partners). IPO on Hong Kong Stock Exchange December 2025. Lead program INS018_055 (idiopathic pulmonary fibrosis) first fully AI-discovered molecule in Phase 2.
Status
active
Tier
master-list
Profitability
—
Pricing
enterprise
FUNDING HISTORY · 0
No funding rounds on file.
PRODUCTS · 0
No products catalogued yet. Press Refresh above to ask the research agent.
TEAM · 0 key people
No people linked.
SOURCES · 0 cited
No citations stored yet. Run the research agent to attach per-claim sources.